Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

BACKGROUND: The anti-interleukin (IL) 6 receptor antibody tocilizumab inhibits signalling of IL6, a key cytokine in rheumatoid arthritis (RA) pathogenesis. OBJECTIVE: To evaluate through the AMBITION study the efficacy and safety of tocilizumab monotherapy versus methotrexate in patients with active...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, G, Sebba, A, Gu, J, Lowenstein, M B, Calvo, A, Gomez-Reino, J J, Siri, D A, Tomšič, M, Alecock, E, Woodworth, T, Genovese, M C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Group 2010
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747519/
https://www.ncbi.nlm.nih.gov/pubmed/19297346
http://dx.doi.org/10.1136/ard.2008.105197

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747519/
https://www.ncbi.nlm.nih.gov/pubmed/19297346
http://dx.doi.org/10.1136/ard.2008.105197

Ejemplares similares